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            The   term   "Electrophysiological   remodeling"   defines   the   changes   of   atrial 
electrophysiologic properties taking place in atrial myocites during atrial fibrillation and/or 
following   periods   of   sustained   atrial   fibrillation   (AF).                                        
Early research was prompted by clinical observations: many patients were seen to get through 
increasingly frequent and longer paroxisms of AF to persistent AF, until chronic AF eventually 
ensued,   without   significant   changes   of   underlying   heart   disease.
            Indeed, clinical electrophysiology investigations reported peculiar differences between 
AF patients and patients without atrial arrhythmias. It was felt that the electrophysiologic milieu 
was the cause of AF 1,2, until a change of perspective occurred in the early 90's, thanks to 
experimental   research.                                                                    
            In his pioneering work, Wijffels kept goats fibrillating by an implanted device, while 
measuring atrial refractoriness and its rate adaptation as spontaneous restoration of sinus rhythm 
occurred. He found that, after several self terminating short bouts of AF, the arrhythmia became 
considerably longer until a duration of days or weeks was reached. The electrophysiologic 
companionship of AF pattern transformation consisted of significant shortening of atrial 
fibrillation cycle, which was paralleled by shortening of atrial ERP and loss of ERP adaptation to 
heart rate: either flat (no change with shortening cycle length) or inverted (paradoxical shorter 
ERP   at   longer   cycle   length)   ERP   relationships   to   cycle   length   were   observed.  
            This findings had been already observed in AF patients1,2; the novelty was that AF itself 
was the cause of these abnormal electrophysiologic properties, which could in turn promote 
further recurrences of AF, and arrhythmia persistence in some cases.                                       
            By the light of this observations, AF may be seen as self-maintaining by creating a 
functional electrophysiologic substratum, despite the coexistence of only minor structural heart 
disease or occasional triggers. This principle has been summarised by Maurits Allessie in the 
aphorism   "AF   begets   AF".                                                                        
            Following this observations, several studies have addressed the issue of the mechanisms 
by   which   atrial   electrophysiologic   remodeling   occurs   in   different   settings:   basic 
electrophysiology,   experimental   electrophysiology,   and   clinical   electrophysiology.   It   is 
nowadays believed that, beyond structural heart disease, changes of the atrial electrophysiologic 
substratum are responsible for AF recurrence and/or perpetuation.                                               
            The aim of this review will be to assess the extent at which atrial remodeling occurs in 
the   experimental   animal   and   in   humans,   and   its   relevance   to   clinical   practice.
Mechanisms   of   atrial   remodeling                                                                      
            Reviewing literature, one has to consider carefully the investigational setting of reported 
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studies, for significant differences exist in electrophysiologic properties and vulnerability to 
atrial arrhythmias among species (small mammals atria hardly fibrillate, dogs and goats only 
under pathologic conditions), so that concepts must lean on solid evidence before moving from 
experimental   to   clinical   electrophysiology,   and   eventually   to   clinical   practice.
             On the other hand, the settings of experimental and basic electrophysiology allow 
precisely controlled conditions, and a deeper knowledge of the mechanisms, up to the 
ionic/genomic level.             It is well demonstrated that atrial remodeling is a time-dependent 
process that develops as an adaptive regulation of cardiac myocites to maintain cell homeostasis 
against external stressors 3. The type and extent of remodeling depends on the strength and the 
duration of exposure to the "stressor": adaptive responses may thus occur at the ionic/genomic 
level (fully reversible) at short term, or at the cellular level at mid (hibernation, usually 
reversible)   and   long   term   (apoptosis   and   fibrosis,   irreversible).
             The most common "stressors" of atrial myocites are: tachycardia (high rate of cell 
depolarisation), and volume/pressure overload (heart failure syndrome).                              
            The adaptive changes at the ionic level are quite different in the tachycardia-dependent 
compared to the heart failure setting, as demonstrated by basic electrophysiology, hence we need 
to focus on different types of "ionic remodeling".                                                       
Tachycardia-dependent remodeling: High atrial rate causes calcium overload. Chronic calcium 
overload may cause ultrastructural changes that resemble myocardial ischemia or hibernation, 
and may ultimately lead to irreversible cell damage. To prevent dangerous calcium overload, 
atrial myocites decrease L-type Ca++ current (ICa) at first by a short-term adaptation (functional 
inactivation   by   voltage-   and   [Ca++]   -   dependent   mechanisms),   in   the   long   term   by 
downregulation of ICa4,5,6,7. Decreased ICa shortens action potential duration (refractoriness) 
and causes loss of action potential adaptation to heart rate6,7: these are the hallmark of 
tachycardia-dependent   remodeling.                                                                      
               The process leading to ICa downregulation implies transcriptional changes at the 
genomic level, but the signal coupling calcium overload to changes in ion channel expression is 
unknown. It also remain to be understood whether calcium overload is the only initiating signal 
in   this   setting.                                                                    
            The observations by Wijffels et al 8 in the experimental animal are in full agreement with 
this model of atrial remodeling. In patients with lone paroxysmal AF, Capucci et al  9 
demonstrated a strict correlation of atrial refractoriness to AF cycle, and observed progressive 
shortening of AF cycle during long lasting AF, whereas AF cycle prolonged in self-terminating 
AF episodes. Acute administration of class 1C drugs was able to prolong AF cycle and terminate 
long lasting AF episodes 10. These data are consistent with basic electrophysiology, and are 
clues that ionic remodeling occurs early during AF, and sets the background for AF recurrence. 
In the clinical scenario, early AF recurrence after cardioversion of chronic AF is the most 
threatened complication. In this setting a typically tachycardia-dependent remodeling occurs: in 
a study of 101 patients 11 we identified loss of atrial refractoriness adaptation to heart rate, short 
atrial refractoriness and AF duration as the only predictors of AF recurrence at logistic analysis.
             In a series of 28 patients, Manios et al  12  similarly observed that failure of action 
potential adaptation  to heart rate  was the only prognostic  indicator  for  AF  recurrence. 
Importantly, they observed that the electrophysiological markers of tachycardia-dependent 
remodeling recover nearly 24 hours after AF cardioversion. This point raises an important 
question, that is, whether loss of refractoriness adaptation to heart rate is the cause of AF relapse 
(which could explain only AF relapse within 24-48 hours) or simply a "marker" of a pathologic 
atrium, which has already undergone some degree of structural remodeling and thus is prone to 
AF. Up to now, the question is unresolved.                                                           
            Owing to this knowledge, a considerable amount of work has been done to test the 
hypothesis that preventing calcium overload by   Icablockers   would   prevent   tachycardia-
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dependent remodeling also. Experimental studies found that pre-treatment with verapamil could 
attenuate 13 or prevent 14 rapid pacing-induced shortening of atrial refractoriness at short term (< 
24 hours of rapid pacing), respectively in goats and dogs. Following these observations, Daoud 
15  reported that pre-treatment with verapamil reduced short-duration (5.6 3.9 minutes) AF-
induced shortening of atrial refractoriness in humans. In the clinical scenario, Tieleman et al 16 
speculated that pre-treatment with verapamil or diltiazem was responsible for reduced AF 
recurrence in the first month after electrical cardioversion, due to attenuated or rapidly reversed 
tachycardia-dependent remodeling.                                                                             
             This hypothesis fits poorly with the electrophysiologic findings by Manios12  who 
demonstrated that atrial remodeling recovers spontaneously nearly 24 hours after cardioversion: 
the role of verapamil is indeed unclear. Clinical studies have failed to demonstrated any 
beneficial effect of verapamil in preventing AF recurrence at long term; indeed, a small effect of 
verapamil pre-treatment could reasonably be expected only in AF of short duration, and does not 
affect the electrophysiologic changes occurring with long-lasting AF 17.                             
            Lee et al17 have performed a very important research in chronically instrumented dogs, 
in which electrophysiologic data were studied at baseline and after creation of a tachycardia-
dependent atrial remodeling, comparing a control group with a verapamil-treated group. Atrial 
refractoriness, dispersion of atrial refractoriness, rate adaptation of atrial refractoriness, atrial 
conduction velocity AF inducibility, and AF duration were evaluated respectively after 1 day, 1 
week, and 6 weeks of rapid atrial pacing. This study demonstrated that verapamil could only 
attenuate   the   refractoriness   shortening   after   1-day   pacing,   but   could   not   prevent   the 
electrophysiologic remodeling at long term (1 and 6 weeks). Furthermore, verapamil did not 
affect atrial inducibility, and increased the duration of induced AF. Consistent with this finding 
is the observation of increased fragmented activity in paroxysmal AF patients treated by 
verapamil, as reported by Kumagay 18, which would favour AF persistence. In his study, Lee 17 
reported a significant depression of atrial conduction velocity after 6 weeks rapid pacing: this 
abnormality had no evidence of recovery during two days of follow-up after pacing had been 
stopped. A similar finding had been previously reported in 2 studies 19,20 of chronic paced dogs, 
and were related to structural abnormalities occurring along time 21. All these data make the 
point that verapamil use is of little value when high atrial rates persist longer than 24 hours, and 
thus   give   an   explanation   to   the   results   observed   in   clinical   practice.
            While demonstrating ICa reduction by downregulation of L-type Ca++ channels, Yue et 
al 6 observed an unchanged inward T-type Ca++ current (ICaT ) even after several weeks of 
rapid atrial pacing, who could thus represent a continuous "spill" of calcium into atrial cells 
undergoing high frequency depolarisations. This prompted Fareh et al 22 to investigate the effect 
of mibefradil, a pure T-type Ca++ blocker, in a chronic rapid-pacing dog model to prevent the 
development of an electrophysiologic substrate for AF. After 1 week of rapid pacing, mibefradil-
treated dogs did not differ from control dogs (no rapid pacing) in any electrophysiologic 
parameter, except for a slightly increased heterogeneity of atrial refractoriness, whereas placebo-
treated  dogs  had  developed  all  the  characteristic  abnormalities  of  tachycardia-dependent 
remodeling (easy AF inducibility included). A potential direct electrophysiologic effect of 
mibefradil was also excluded in this study, thus supporting the evidence that prevention of 
tachycardia-induced remodeling as the only protective effect of mibefradil. Indeed, the AF-
promoting   effects   of   rapid   pacing   were   negatively   correlated   to   mibefradil   plasma 
concentrations,   showing   a   dose-dependent   protection   against   atrial   remodeling.
             In a similar study on dogs, Fareh et al  23  also demonstrated that prevention of 
tachycardia-dependent remodeling is possible with the T-type Ca++ channel blocker mibefradil, 
but   not  with  L-type   Ca++   channel  blockers.                                                          
             There is considerable evidence that, in tachycardia-dependent remodeling, calcium 
overload plays an important role either at short or at long term if high atrial rates persist. In the 
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clinical setting, small benefits may be observed at short term by verapamil, whereas T-type 
Ca++ channel blockers seem promising to prevent long term remodeling during persistent AF.
            These data support the concept that new therapies should target the development of the 
substrate for AF, as opposed to "traditional" antiarrhythmic therapy which aims to modify the 
product  of   the  arrhythmic  substrate.                                                                      
Heart failure-dependent remodeling: Heart failure (HF) is the most important clinical syndrome 
associated to AF 24. Heart failure causes important ionic remodeling either at the atrial or at the 
ventricular level by powerful neurohormonal changes. The study of atrial remodeling in HF is 
very difficult in humans because of the structural changes caused by underlying myocardial 
pathology, and because of the confounding effect of drugs acting on the neurohormonal milieu 
and of antiarrhythmic agents. For this reason most of available data rely upon basic and 
experimental research, most often on ventricular myocites.                                                 
             Heavy alterations in calcium handling are prominent in ventricular myocites: the 
sarcoplasmic carrier of Ca++ is downregulated in failing myocites  25, leading to increased 
cytosolic [Ca++] as a maladaptive attempt to maintain contractility. Sodium-calcium exchanger 
current (NCX) is instead upregulated in HF, acting to compensate the impaired Ca++ removal 
due to the sarcoplasmic carrier  26,27,28, to protect contractile function and cellular Ca++ 
homeostasis. NCX exchanges one Ca++ for three Na+ , thus carrying a net current in the 
direction   of   Na+   transport.   The   net   current   carried   by   NCX   may   cause   delayed 
afterdepolarisation   (DAD)   in   certain   electrophysiologic   situations,   which   proved   to   be 
arrhythmogenic   in   HF  29.                                                              
            Danshi li et al. 30 created a canine model of rapid ventricular pacing-induced HF, and 
observed for the first time in atrial myocites a decrease in ICa, in Na+ current (Ito), in slow 
rectifying K+ current (Iks), and an increase in NCX. Heart failure decreased both Iks and ICa 
30%,   whereas   atrial   tachycardia   decreases   ICa   70%   without   affecting   Ik  6.   The 
electrophysiologic manifestations were an unchanged action potential duration (APD) at slow 
heart rates compared to control dogs, whereas an increase of APD at faster high rates was 
observed.
             Thus, a peculiar type of remodeling with an attenuated rate-adaptation of atrial 
refractoriness and long APD at high rates is observed in experimental HF. This is quite different 
from atrial tachycardia-dependent remodeling, which shows decreased APD at any cycle length 
and flat or reversed adaptation of refractoriness to heart rate.                                             
            The mechanisms of AF onset in the setting of HF must be very different. Structural 
changes (interstitial fibrosis) related to underlying disease cause conduction abnormalities that 
predispose to reentrant arrhythmias, increased NCX may promote DADs by transient inward 
depolarising current, which may be enhanced by high cathecolamine levels and by decreased 
Iks. It seems then likely that AF may be initiated by triggered activity, in the HF setting. 
            If a different sort of atrial remodeling occurs in HF, peculiar interventions for targeting 
this arrhythmogenic substrate should be sought.                                                                 
            Danshi Li and co-workers 31 performed an elegant investigation on 15 dogs with HF 
induced by rapid ventricular pacing compared to 10 dogs without HF subjected to rapid atrial 
pacing (RAP), evaluating the effect of dofetilide on vulnerability to AF. It was observed that 
dofetilide, a pure Ikr blocker, was extremely effective in terminating AF and in preventing AF 
reinduction in dogs with HF-dependent AF. On the contrary, dofetilide was completely 
ineffective in dogs with atrial tachycardia-dependent AF. The electrophysiologic findings were 
striking: atrial refractoriness was shorter and showed less rate adaptation in RAP vs HF dogs; 
dofetilide increased refractoriness significantly and to a greater extent in HF dogs, whereas it 
had   nonsignificant   effects   in   RAP   dogs.                                                            
            This finding was related to the increased dependency of atrial refractoriness on Ikr in HF 
dogs,  due  to  downregulation  of  Iks  occurring  in  HF  dogs.                                      
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            Significant clinical results were indeed observed by Torp-Pedersen et al 32 investigating 
dofetilide effects in advanced HF patients (class III-IV): a significant proportion of AF patient 
converted to sinus rhythm by dofetilide, and dofetilide patients had a significantly higher 
proportion of sinus rhythm persistence during clinical follow up compared to control patients.
            Nonetheless, AF incidence increases with the severity and the duration of HF despite 
therapeutic   interventions.                                                  
             Shinigawa et al33  studied the electrophysiologic remodeling occurring during atrial 
tachycardia in a canine model when HF was superimposed, and also after reversal of HF was 
allowed to take place. They observed that the electrophysiologic changes related to atrial 
tachycardia were completely attenuated by HF, and that reversal of HF led to normalisation of 
both ventricular and atrial volume and contractility, with recovery of atrial electrophysiologic 
abnormalities. However, extensive interstitial fibrosis had developed compared to a group of 
control dogs, and this invariably caused local conduction slowing and heterogeneity of 
conduction velocity. This changes were irreversible.                                                       
            Interestingly, in the same experimental canine model of HF, Danshi Li et al 34 reported 
that angiotensin II causes structural atrial remodeling inducing collagen synthesis by fibroblasts, 
and that enalapril interferes with signal transduction at the cellular level, thereby reducing the 
amount of interstitial fibrosis by 30% compared to control dogs or to hydralazine-treated dogs. 
             These two studies carry the important notion of targeting the development of the 
arrhythmogenic substrate understanding the pathophysiologic mechanisms of the disease or of 
the   clinical   syndrome.                                                          
            It is interesting to note that, either in atrial tachycardia-dependent or in HF-dependent 
remodeling, both reversible and irreversible changes occur. In either situation, the abnormalities 
due to ionic remodeling (APD, refractoriness and its adaptation to heart rate) appear to be 
reversible when the "stressor" is removed, but in the same time structural changes at the cellular 
level have occurred, which are irreversible. This "structural remodeling" adds slowing and 
heterogeneity of conduction velocity to the abnormalities of refractoriness in both situations, and 
may explain the reduced efficacy of medical interventions in patients with persistent or 
permanent   AF.                                                          
            Experimental research has clearly demonstrated that "electrophysiologically" different 
arrhythmias share a common electrocardiographic picture of atrial fibrillation, and that the 
underlying differences imply peculiar therapeutic interventions.                                                     
             All these investigations have brought in the clinical arena a new way of thinking 
antiarrhythmic therapy: development of new drugs should be guided by the principle of targeting 
the specific ionic currents depending on the pathophysiologic mechanisms of the arrhythmia, to 
achieve the optimal ratio between efficacy and safety. Also, the concept of preventing structural 
remodeling of atrial myocites should be investigated and promptly brought into clinical practice.
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